



Learn About INTRAROSA® (prasterone) vaginal inserts

A novel treatment for moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy (VVA), due to menopause¹

Indication

INTRAROSA is a steroid indicated for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause.

Important Safety Information

INTRAROSA is contraindicated in women with undiagnosed abnormal genital bleeding. Estrogen is a metabolite of prasterone. Use of exogenous estrogen is contraindicated in women with a known or suspected history of breast cancer. INTRAROSA has not been studied in women with a history of breast cancer.

In four 12-week randomized, placebo-controlled clinical trials, the most common adverse reaction with an incidence \geq 2 percent was vaginal discharge. In one 52-week open-label clinical trial, the most common adverse reactions with an incidence \geq 2 percent were vaginal discharge and abnormal Pap smear.





INTERESTED IN LEARNING MORE?

Please join us as we discuss

- VVA Due to Menopause: Focus on Moderate to Severe Dyspareunia
- A Novel Treatment for Moderate to Severe Dyspareunia Due to Menopause

Thursday, July 12, 2018 at 6:30 PM

Featured Speaker

Maureen Whelihan, MD, FACOG

The speaker is contracted to speak on behalf of AMAG Pharmaceuticals, Inc.

Venue: La Grotta
9520 Marketplace Road
Ft. Myers, FL 33912

RSVP to: <http://pharmethodportal.com/AMAG/register>
Meeting ID: 13484 or Kaley Voss at 727-686-6697

1. INTRAROSA® (prasterone) Prescribing Information. AMAG Pharmaceuticals, Inc.

Please see Indication and Important Safety Information on page 1.

Please also see accompanying full Prescribing Information.

INTRAROSA is a registered trademark of Endoceutics, Inc.
Distributed by AMAG Pharmaceuticals, Inc., Waltham, MA 02451
©2017 AMAG Pharmaceuticals, Inc. PP-INR-US-00191 11/17

